TNXP Tonix Pharmaceuticals Holding Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TNXP

Price (delayed)

$0.1579

Market cap

$13.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.85

Enterprise value

-$1.79M

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's ...

Highlights
The company's revenue has surged by 95% QoQ
The gross profit has soared by 87% from the previous quarter
TNXP's quick ratio has soared by 175% from the previous quarter but it has plunged by 80% YoY
The net income has declined by 6% year-on-year but it has increased by 3.6% since the previous quarter
The company's equity fell by 49% YoY and by 13% QoQ
TNXP's gross margin is down by 3.7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tonixpharma.com
Peers: SCYX ANIP UTHR EGRX

Key stats

What are the main financial stats of TNXP
Market
Shares outstanding
84.49M
Market cap
$13.34M
Enterprise value
-$1.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.04
Price to sales (P/S)
0.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.23
Earnings
Revenue
$7.77M
EBIT
-$116.66M
EBITDA
-$112.37M
Free cash flow
-$108.9M
Per share
EPS
-$6.85
Free cash flow per share
-$6.39
Book value per share
$4.42
Revenue per share
$0.46
TBVPS
$8.44
Balance sheet
Total assets
$154.46M
Total liabilities
$48.93M
Debt
$9.81M
Equity
$105.53M
Working capital
$28.88M
Liquidity
Debt to equity
0.09
Current ratio
2.53
Quick ratio
1.32
Net debt/EBITDA
0.13
Margins
EBITDA margin
-1,446.5%
Gross margin
39%
Net margin
-1,501.8%
Operating margin
-1,523.9%
Efficiency
Return on assets
-73.8%
Return on equity
-87.7%
Return on invested capital
-112.3%
Return on capital employed
-86%
Return on sales
-1,501.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TNXP stock price

How has the Tonix Pharmaceuticals Holding stock price performed over time
Intraday
-1.31%
1 week
-1.31%
1 month
-54.36%
1 year
-99.14%
YTD
-60.82%
QTD
-15.11%

Financial performance

How have Tonix Pharmaceuticals Holding's revenue and profit performed over time
Revenue
$7.77M
Gross profit
$3.03M
Operating income
-$118.38M
Net income
-$116.66M
Gross margin
39%
Net margin
-1,501.8%
The company's revenue has surged by 95% QoQ
The gross profit has soared by 87% from the previous quarter
Tonix Pharmaceuticals Holding's operating margin has soared by 51% from the previous quarter
The net margin has surged by 50% since the previous quarter

Growth

What is Tonix Pharmaceuticals Holding's growth rate over time

Valuation

What is Tonix Pharmaceuticals Holding stock price valuation
P/E
N/A
P/B
0.04
P/S
0.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.23
TNXP's EPS has soared by 66% YoY and by 25% from the previous quarter
The P/B is 94% lower than the 5-year quarterly average of 0.7 and 60% lower than the last 4 quarters average of 0.1
The company's equity fell by 49% YoY and by 13% QoQ
The company's revenue has surged by 95% QoQ

Efficiency

How efficient is Tonix Pharmaceuticals Holding business performance
The company's return on equity has shrunk by 64% YoY and by 13% QoQ
TNXP's ROA has shrunk by 53% YoY and by 5% QoQ
TNXP's ROS has soared by 50% from the previous quarter
TNXP's return on invested capital is up by 16% year-on-year and by 9% since the previous quarter

Dividends

What is TNXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNXP.

Financial health

How did Tonix Pharmaceuticals Holding financials performed over time
TNXP's quick ratio has soared by 175% from the previous quarter but it has plunged by 80% YoY
Tonix Pharmaceuticals Holding's total liabilities has soared by 165% from the previous quarter and by 164% YoY
The debt is 91% smaller than the equity
The company's equity fell by 49% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.